In:
Clinical and Translational Oncology, Springer Science and Business Media LLC, Vol. 24, No. 10 ( 2022-06-23), p. 2039-2043
Abstract:
To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. Methods/patients Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if 〉 5 Gy/fraction were delivered. Results Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). Conclusion Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.
Type of Medium:
Online Resource
ISSN:
1699-3055
DOI:
10.1007/s12094-022-02844-5
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2022
detail.hit.zdb_id:
2420460-2